EP2291191A4 - Methods for preventing and treating neurodegenerative diseases - Google Patents

Methods for preventing and treating neurodegenerative diseases

Info

Publication number
EP2291191A4
EP2291191A4 EP09743804.8A EP09743804A EP2291191A4 EP 2291191 A4 EP2291191 A4 EP 2291191A4 EP 09743804 A EP09743804 A EP 09743804A EP 2291191 A4 EP2291191 A4 EP 2291191A4
Authority
EP
European Patent Office
Prior art keywords
preventing
methods
neurodegenerative diseases
treating neurodegenerative
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09743804.8A
Other languages
German (de)
French (fr)
Other versions
EP2291191A1 (en
Inventor
Giulio Maria Pasinetti
Lap Ho
Jun Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Mount Sinai School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai School of Medicine filed Critical Mount Sinai School of Medicine
Publication of EP2291191A1 publication Critical patent/EP2291191A1/en
Publication of EP2291191A4 publication Critical patent/EP2291191A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
EP09743804.8A 2008-05-09 2009-05-08 Methods for preventing and treating neurodegenerative diseases Withdrawn EP2291191A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5186608P 2008-05-09 2008-05-09
PCT/US2009/043392 WO2009137818A1 (en) 2008-05-09 2009-05-08 Methods for preventing and treating neurodegenerative diseases

Publications (2)

Publication Number Publication Date
EP2291191A1 EP2291191A1 (en) 2011-03-09
EP2291191A4 true EP2291191A4 (en) 2014-01-22

Family

ID=41265046

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09743804.8A Withdrawn EP2291191A4 (en) 2008-05-09 2009-05-08 Methods for preventing and treating neurodegenerative diseases

Country Status (11)

Country Link
US (1) US8747924B2 (en)
EP (1) EP2291191A4 (en)
JP (1) JP5738755B2 (en)
KR (1) KR101705766B1 (en)
CN (2) CN102083444A (en)
AU (1) AU2009244057B2 (en)
CA (1) CA2725546C (en)
IL (1) IL209216A (en)
NZ (1) NZ589807A (en)
RU (1) RU2496502C2 (en)
WO (1) WO2009137818A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871716B2 (en) 2010-10-08 2014-10-28 Korea Advanced Institute Of Science And Technology Use of antimicrobial peptides in regeneration of skin cells
WO2012138190A2 (en) 2011-04-06 2012-10-11 한국생명공학연구원 Composition containing jetbead extracts
WO2012138034A1 (en) 2011-04-06 2012-10-11 한국생명공학연구원 Pharmaceutical composition for the prevention or treatment of a neurodegenerative disease, comprising a daphne genkwa extract or a compound isolated therefrom
CN103877144B (en) * 2013-05-02 2017-02-22 杭州耐奇睿生物医药科技有限公司 Application of peanut coat active component and composition comprising peanut coat active component
AU2014270338A1 (en) * 2013-05-24 2015-10-08 Nestec S.A. Treatment or prevention of neurodegenerative disorders using Menthol, Linalool and/or Icilin
JP6370674B2 (en) 2014-10-22 2018-08-08 国立研究開発法人国立長寿医療研究センター Tauopathy drug and screening method thereof
WO2016072522A1 (en) * 2014-11-06 2016-05-12 国立大学法人 長崎大学 Novel therapeutic agent for alzheimer's disease
KR20170032815A (en) * 2015-09-15 2017-03-23 경희대학교 산학협력단 Novel lactic acid bacteria and composition for preventing, improving or treating neurodegenerative diseases or cognitive dysfunction
JP6735224B2 (en) 2016-01-28 2020-08-05 花王株式会社 Activator of glucose metabolism in astrocytes
BR112018073472A2 (en) 2016-05-18 2019-08-27 Voyager Therapeutics Inc Huntington's disease treatment compositions and methods
JP6416828B2 (en) * 2016-06-23 2018-10-31 株式会社レーネ Tau protein aggregation inhibitor
KR101910153B1 (en) * 2016-11-04 2018-10-19 한국과학기술연구원 Levosimendan compounds for preventing or treating tau related disease
EP3689156A4 (en) * 2017-09-29 2021-06-30 Suntory Holdings Limited Composition for promoting expression of aquaporin 3
JP2019007963A (en) * 2018-07-09 2019-01-17 国立研究開発法人国立長寿医療研究センター Tauopathy therapeutic agent and screening method thereof
CN111012759B (en) * 2019-12-19 2021-09-07 暨南大学 NGF-loaded flower-shaped ruthenium nano particle, preparation method and application thereof in Alzheimer's disease
JP2023527420A (en) * 2020-05-28 2023-06-28 ポステック・リサーチ・アンド・ビジネス・ディヴェロップメント・ファウンデイション Composition for prevention or treatment of degenerative brain disease, containing hibiscus, rosemary and grape seed extract as active ingredients
CN114181201B (en) * 2020-09-15 2023-12-01 香港科技大学 Novel compounds as potential therapeutic agents against various neurodegenerative diseases
KR102231446B1 (en) * 2021-01-21 2021-03-24 (주) 와이디생명과학 Pharmaceutical composition for treating the diseases related to the aggregation of beta amyloid and tau proteins

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08225453A (en) * 1994-11-28 1996-09-03 Suntory Ltd Lipoprotein (a) depressor, cholesterol depressor and medicine containing the same
JPH09221484A (en) * 1996-02-14 1997-08-26 Kikkoman Corp Production of proanthocyanidin
US20030017998A1 (en) * 1997-05-16 2003-01-23 Snow Alan D. Proanthocyanidins for the treatment of amyloid and alpha-synuclein diseases
US6544581B1 (en) 1999-06-22 2003-04-08 Canandaigua Wine Company, Inc. Process for extraction, purification and enrichment of polyphenolic substances from whole grapes, grape seeds and grape pomace
JP4380991B2 (en) * 2001-03-15 2009-12-09 プロテオテック・インコーポレーテッド Proanthocyanidins for the treatment of amyloid and alpha synuclein diseases
CA2440293C (en) * 2001-03-15 2012-01-24 Proteotech, Inc. Catechins for the treatment of fibrillogenesis in alzheimer's disease, parkinson's disease, systemic aa amyloidosis, and other amyloid disorders
US20040115285A1 (en) * 2002-12-13 2004-06-17 Peter Rohdewald Method of normalizing glucose levels in blood of patients with diabetes mellitus by oral administration of proanthocyanidins containing plant extracts
KR100543056B1 (en) * 2003-11-07 2006-01-20 (주)네추럴에프앤피 Composition comprising grape seed extract having neuronal cell-protecting activity for preventing and treating brain disease
JP4941991B2 (en) * 2005-02-25 2012-05-30 国立大学法人 長崎大学 Proanthocyanidin oligomer production method
ES2542713T3 (en) 2005-09-28 2015-08-10 Constellation Brands, Inc. Grape extract, dietary supplement and preparation procedure

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Researchers Present Alzheimer's and Autism Breakthroughs", 11 July 2007 (2007-07-11), XP055094140, Retrieved from the Internet <URL:http://www.newswise.com/articles/researchers-present-alzheimers-and-autism-breakthroughs> [retrieved on 20131218] *
ELISA FERRER ET AL: "Highlights of the 37th Annual Meeting of the Society for Neuroscience", DRUGS OF THE FUTURE 2007, vol. 32, no. 12, 1 January 2007 (2007-01-01), pages 1081 - 1095, XP055094159 *
See also references of WO2009137818A1 *

Also Published As

Publication number Publication date
US8747924B2 (en) 2014-06-10
KR20110013466A (en) 2011-02-09
AU2009244057B2 (en) 2013-11-28
CN102083444A (en) 2011-06-01
WO2009137818A1 (en) 2009-11-12
AU2009244057A1 (en) 2009-11-12
CA2725546C (en) 2018-07-31
IL209216A (en) 2016-03-31
EP2291191A1 (en) 2011-03-09
JP2011520814A (en) 2011-07-21
KR101705766B1 (en) 2017-02-10
NZ589807A (en) 2012-11-30
RU2496502C2 (en) 2013-10-27
CN105920216A (en) 2016-09-07
JP5738755B2 (en) 2015-06-24
US20110111072A1 (en) 2011-05-12
IL209216A0 (en) 2011-01-31
CA2725546A1 (en) 2009-11-12
RU2010150478A (en) 2012-06-20

Similar Documents

Publication Publication Date Title
IL209216A0 (en) Methods for preventing and treating neurodegenerative diseases
HK1162366A1 (en) Devices and methods for treating and or preventing diseases
EP2176283A4 (en) Methods and compositions for treating brain diseases
EP2432476A4 (en) Methods for treating or preventing ophthalmological diseases
EP2521724A4 (en) Agents and methods for treating ischemic and other diseases
HK1156631A1 (en) Novel compounds and methods for therapy
IL212348A0 (en) Treatment method
PT2252148T (en) Methods for treating bowel diseases
EP2497482A4 (en) Composition for preventing and treating influenza-virus-induced diseases
EP2170311A4 (en) Compounds and methods for treating or preventing autoimmune diseases
HK1158172A1 (en) Compounds for treating ophthalmic diseases and disorders
IL209895A (en) Compounds for preventing and/or treating ß -amyloidoses
EP2300011A4 (en) Therapeutic methods and compounds
EP2365747A4 (en) Methods for treating gastrointestinal diseases
EP2611765A4 (en) Methods for treating neurodegenerative diseases
EP2262366A4 (en) Compounds and methods for treating estrogen receptor-related diseases
EP2341936A4 (en) METHODS FOR TREATING OR PREVENTING IL-1ß RELATED DISEASES
IL204728A0 (en) Methods and compounds for treating retinol-related diseases
GB0819280D0 (en) Imgaing and radiotherapy methods
EP2334313A4 (en) Homeopathic therapeutic method
GB0915259D0 (en) Sulphur-linked compounds for treating ophthalmic diseases and disorders
HK1149545A1 (en) Compositions and methods for treating ophthalmic diseases
IL210840A0 (en) Methods and compositions for treating and preventing autoimmune diseases
EP2552446A4 (en) Method for treating schizophrenia and related diseases
GB0718684D0 (en) Treatment method

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20101207

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA RS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MOUNT SINAI SCHOOL OF MEDICINE

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20140107

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 45/06 20060101ALI20131219BHEP

Ipc: A61K 31/353 20060101ALI20131219BHEP

Ipc: A61K 36/87 20060101ALI20131219BHEP

Ipc: A61K 31/7048 20060101AFI20131219BHEP

17Q First examination report despatched

Effective date: 20151020

APBK Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNE

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20191203